187 related articles for article (PubMed ID: 26540631)
21. Identifying Clinically Relevant Proteins for Targeted Analysis in the Development of a Multiplexed Proteomic Biomarker Assay.
Mackay EM; Bathe OF
Methods Mol Biol; 2018; 1788():123-129. PubMed ID: 29569121
[TBL] [Abstract][Full Text] [Related]
22. Proteomics discovery of radioresistant cancer biomarkers for radiotherapy.
Chang L; Graham P; Hao J; Bucci J; Malouf D; Gillatt D; Li Y
Cancer Lett; 2015 Dec; 369(2):289-97. PubMed ID: 26427840
[TBL] [Abstract][Full Text] [Related]
23. Differential membrane proteomics using 18O-labeling to identify biomarkers for cholangiocarcinoma.
Kristiansen TZ; Harsha HC; Grønborg M; Maitra A; Pandey A
J Proteome Res; 2008 Nov; 7(11):4670-7. PubMed ID: 18839982
[TBL] [Abstract][Full Text] [Related]
24. Improving the computational efficiency of recursive cluster elimination for gene selection.
Luo LK; Huang DF; Ye LJ; Zhou QF; Shao GF; Peng H
IEEE/ACM Trans Comput Biol Bioinform; 2011; 8(1):122-9. PubMed ID: 20479497
[TBL] [Abstract][Full Text] [Related]
25. Coherent pipeline for biomarker discovery using mass spectrometry and bioinformatics.
Al-Shahib A; Misra R; Ahmod N; Fang M; Shah H; Gharbia S
BMC Bioinformatics; 2010 Aug; 11():437. PubMed ID: 20796299
[TBL] [Abstract][Full Text] [Related]
26. DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery.
Zhu T; Zhu Y; Xuan Y; Gao H; Cai X; Piersma SR; Pham TV; Schelfhorst T; Haas RRGD; Bijnsdorp IV; Sun R; Yue L; Ruan G; Zhang Q; Hu M; Zhou Y; Van Houdt WJ; Le Large TYS; Cloos J; Wojtuszkiewicz A; Koppers-Lalic D; Böttger F; Scheepbouwer C; Brakenhoff RH; van Leenders GJLH; Ijzermans JNM; Martens JWM; Steenbergen RDM; Grieken NC; Selvarajan S; Mantoo S; Lee SS; Yeow SJY; Alkaff SMF; Xiang N; Sun Y; Yi X; Dai S; Liu W; Lu T; Wu Z; Liang X; Wang M; Shao Y; Zheng X; Xu K; Yang Q; Meng Y; Lu C; Zhu J; Zheng J; Wang B; Lou S; Dai Y; Xu C; Yu C; Ying H; Lim TK; Wu J; Gao X; Luan Z; Teng X; Wu P; Huang S; Tao Z; Iyer NG; Zhou S; Shao W; Lam H; Ma D; Ji J; Kon OL; Zheng S; Aebersold R; Jimenez CR; Guo T
Genomics Proteomics Bioinformatics; 2020 Apr; 18(2):104-119. PubMed ID: 32795611
[TBL] [Abstract][Full Text] [Related]
27. Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues.
Kawase H; Fujii K; Miyamoto M; Kubota KC; Hirano S; Kondo S; Inagaki F
J Proteome Res; 2009 Aug; 8(8):4092-103. PubMed ID: 19569727
[TBL] [Abstract][Full Text] [Related]
28. Biomarker discovery with SELDI-TOF MS in human urine associated with early renal injury: evaluation with computational analytical tools.
Vanhoutte KJ; Laarakkers C; Marchiori E; Pickkers P; Wetzels JF; Willems JL; van den Heuvel LP; Russel FG; Masereeuw R
Nephrol Dial Transplant; 2007 Oct; 22(10):2932-43. PubMed ID: 17616539
[TBL] [Abstract][Full Text] [Related]
29. A Combined Shotgun and Targeted Mass Spectrometry Strategy for Breast Cancer Biomarker Discovery.
Sjöström M; Ossola R; Breslin T; Rinner O; Malmström L; Schmidt A; Aebersold R; Malmström J; Niméus E
J Proteome Res; 2015 Jul; 14(7):2807-18. PubMed ID: 25944384
[TBL] [Abstract][Full Text] [Related]
30. Tissue culture-based breast cancer biomarker discovery platform.
Kulasingam V; Diamandis EP
Int J Cancer; 2008 Nov; 123(9):2007-12. PubMed ID: 18712711
[TBL] [Abstract][Full Text] [Related]
31. Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology.
Hu X; Zhang Y; Zhang A; Li Y; Zhu Z; Shao Z; Zeng R; Xu LX
OMICS; 2009 Aug; 13(4):291-300. PubMed ID: 19624269
[TBL] [Abstract][Full Text] [Related]
32. Why have so few proteomic biomarkers "survived" validation? (Sample size and independent validation considerations).
Hernández B; Parnell A; Pennington SR
Proteomics; 2014 Jul; 14(13-14):1587-92. PubMed ID: 24737731
[TBL] [Abstract][Full Text] [Related]
33. Global and targeted quantitative proteomics for biomarker discovery.
Veenstra TD
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Feb; 847(1):3-11. PubMed ID: 17023222
[TBL] [Abstract][Full Text] [Related]
34. Proteomic cancer classification with mass spectrometry data.
Rajapakse JC; Duan KB; Yeo WK
Am J Pharmacogenomics; 2005; 5(5):281-92. PubMed ID: 16196498
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis of early relapse in ovarian cancer using serum proteomic profiling.
Oh JH; Gao J; Nandi A; Gurnani P; Knowles L; Schorge J
Genome Inform; 2005; 16(2):195-204. PubMed ID: 16901102
[TBL] [Abstract][Full Text] [Related]
36. Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture.
Paul D; Kumar A; Gajbhiye A; Santra MK; Srikanth R
Biomed Res Int; 2013; 2013():783131. PubMed ID: 23586059
[TBL] [Abstract][Full Text] [Related]
37. Toward an integrated pipeline for protein biomarker development.
Drabovich AP; Martínez-Morillo E; Diamandis EP
Biochim Biophys Acta; 2015 Jun; 1854(6):677-86. PubMed ID: 25218201
[TBL] [Abstract][Full Text] [Related]
38. Differential proteomic and tissue expression analyses identify valuable diagnostic biomarkers of hepatocellular differentiation and hepatoid adenocarcinomas.
Reis H; Padden J; Ahrens M; Pütter C; Bertram S; Pott LL; Reis AC; Weber F; Juntermanns B; Hoffmann AC; Eisenacher M; Schlaak JF; Canbay A; Meyer HE; Sitek B; Baba HA
Pathology; 2015 Oct; 47(6):543-50. PubMed ID: 26308133
[TBL] [Abstract][Full Text] [Related]
39. Batch effects correction improves the sensitivity of significance tests in spectral counting-based comparative discovery proteomics.
Gregori J; Villarreal L; Méndez O; Sánchez A; Baselga J; Villanueva J
J Proteomics; 2012 Jul; 75(13):3938-51. PubMed ID: 22588121
[TBL] [Abstract][Full Text] [Related]
40. MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers.
Deininger SO; Ebert MP; Fütterer A; Gerhard M; Röcken C
J Proteome Res; 2008 Dec; 7(12):5230-6. PubMed ID: 19367705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
